Gwangju Institute of Science and Technology

Molecular testing for KIT mutations remains critical in gastrointestinal stromal tumor (GIST) diagnosis, with imatinib producing dramatic early responses in over 90% of patients.

NCCN guidelines establish a clear sequential treatment approach for metastatic GIST, with imatinib as first-line, followed by sunitinib, regorafenib, and ripretinib in subsequent lines.

Onco360, the nation's leading independent specialty pharmacy, has been selected as a national pharmacy partner for QINLOCK (ripretinib), an FDA-approved treatment for advanced gastrointestinal stromal tumors.

Cogent Biosciences secured a $400 million non-dilutive debt financing facility with SLR Capital Partners, with an initial $50 million already drawn to support the company's growth strategy.

Kura Oncology has dosed first patients in KOMET-015, a Phase 1 trial evaluating ziftomenib in combination with imatinib for advanced gastrointestinal stromal tumors (GIST) after imatinib failure.

A 57-year-old female with a large gastrointestinal stromal tumor (GIST) achieved successful R0 resection after neoadjuvant ripretinib therapy, marking the first reported case of ripretinib use in this setting.

Hoth Therapeutics' novel therapy HT-KIT demonstrated significant efficacy in reducing KIT receptor expression and inducing tumor cell death within 24 hours in preclinical GIST models.

New research demonstrates that CT imaging can accurately predict surgical benefits of neoadjuvant TKI treatment in non-metastatic GIST patients within 3 months of treatment initiation.

Phase 3 Peak study shows bezuclastinib combined with sunitinib improves outcomes in gastrointestinal stromal tumors (GIST) compared to sunitinib alone.

Cogent Biosciences will present a poster on bezuclastinib at the AAAAI Annual Meeting, focusing on long-term symptomatic benefits in NonAdvSM patients.